Table 3.
Demographic and clinical characteristics of the hypoalgesic and other CD cohorts
| Variable | Hypoalgesic CD | Other CD | P value |
| Cohort (% women) | 43 (37.2%) | 218 (60.6%) | 0.005 |
| Age (yr) | 46.3 ± 1.9 | 43.1 ± 0.8 | 0.10 |
| BMI | 25.6 ± 0.8 | 28.8 ± 1.2 | 0.14 |
| Race (AI-AN/Asian/BoAA/White) | 0/2/3/38 | 3/13/20/182 | 0.80 |
| Disease location (Montreal) | |||
| L1 | 7 (16.3%) | 62 (28.4%) | 0.33 |
| L2 | 11 (25.6%) | 38 (17.4%) | |
| L3 | 25 (58.1%) | 118 (54.2%) | |
| L4 | 2 (4.7%) | 11 (5.0%) | |
| Crohn's disease behavior (Montreal) | |||
| Nonstricturing/nonpenetrating (B1) | 11 (25.6%) | 85 (39.0%) | 0.08 |
| Stricturing (B2) | 14 (32.6%) | 75 (34.4%) | 0.82 |
| Penetrating (B3) | 18 (41.8%) | 58 (26.6%) | 0.04 |
| Disease duration (yr) | 10.7 ± 1.4 | 12.8 ± 0.7 | 0.31 |
| Any history of EIM | 20 (46.5%) | 134 (61.5%) | 0.09 |
| Short Inflammatory Bowel Disease Questionnaire | 57.8±1.5 | 44.7±0.9 | <0.001 |
| Pain scores (SIBDQ4 = 6/SIBDQ4 = 7) | 18/25 | ||
| Harvey-Bradshaw Index | 3.3±0.4 | 6.9±0.3 | <0.001 |
| Prior history of surgery (CD) | 18 (41.8%) | 101 (46.3%) | 0.62 |
| Laboratory studies | |||
| WBC (103 cells/mm3) | 8.4 ± 0.6 | 7.8 ± 0.3 | 0.57 |
| ESR (mm/hr) | 17.8 ± 3.3 | 17.9 ± 1.7 | 0.73 |
| CRP (mg/dL) | 1.6 ± 0.5 | 1.2 ± 0.1 | 0.70 |
| Current IBD medications | |||
| Corticosteroid | 1 (2.3%) | 24 (11.0%) | 0.08 |
| Mesalamine | 7 (16.3%) | 28 (13.1%) | 0.62 |
| Immunomodulator | 17 (39.5%) | 55 (25.2%) | 0.06 |
| Biologic | 29 (67.4%) | 153 (70.2%) | 0.72 |
| Active pain medication/substance use | |||
| Tobacco use | 5 (11.6%) | 25 (11.6%) | 1.0 |
| Alcohol use | 15 (34.9%) | 53 (24.3%) | 0.18 |
| Cannabis use | 1 (2.3%) | 16 (7.3%) | 0.32 |
| Illicit drug use | 3 (7.0%) | 12 (5.5%) | 0.72 |
| NSAID use | 8 (18.6%) | 29 (13.3%) | 0.35 |
| Opioid use | 0 (0.0%) | 26 (11.9%) | 0.01 |
| Other pain medication use | 10 (23.3%) | 91 (41.7%) | 0.03 |
| Symptoms of anxiety/depression | 13 (30.2%) | 120 (55.0%) | 0.004 |
| Antidepressant/anxiolytic use | 4 (9.3%) | 84 (38.5%) | <0.001 |
Individuals with L4 (Crohn’s disease of the upper gastrointestinal tract) could exhibit this disease distribution in addition to disease at other sites in the gut.
AI-AN, American Indian-Alaska Native; BMI, body mass index; BoAA, Black or African American; CD, Crohn's disease; CRP, C-reactive protein; EIM, extraintestinal manifestation; ESR, sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug; IBD, inflammatory bowel disease; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; SIBDQ4, SIBDQ Pain Score (note: a SIBDQ4 score of 6 indicates abdominal pain hardly any of the time over the prior 2 wk period, while a score of 7 indicates no pain).
Items in bold-italics demonstrated statistically significant differences from one another.